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A PI3K p110b–Rac signalling loop mediates
Pten-loss-induced perturbation of haematopoiesis
and leukaemogenesis
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The tumour suppressor PTEN, which antagonizes PI3K signalling, is frequently inactivated in
haematologic malignancies. In mice, deletion of PTEN in haematopoietic stem cells (HSCs)
causes perturbed haematopoiesis, myeloproliferative neoplasia (MPN) and leukaemia.
Although the roles of the PI3K isoforms have been studied in PTEN-deﬁcient tumours, their
individual roles in PTEN-deﬁcient HSCs are unknown. Here we show that when we delete
PTEN in HSCs using the Mx1–Cre system, p110b ablation prevents MPN, improves HSC
function and suppresses leukaemia initiation. Pharmacologic inhibition of p110b in
PTEN-deﬁcient mice recapitulates these genetic ﬁndings, but suggests involvement of both
Akt-dependent and -independent pathways. Further investigation reveals that a p110b–Rac
signalling loop plays a critical role in PTEN-deﬁcient HSCs. Together, these data suggest that
myeloid neoplasia driven by PTEN loss is dependent on p110b via p110b–Rac-positive-feed-
back loop, and that disruption of this loop may offer a new and effective therapeutic strategy
for PTEN-deﬁcient leukaemia.
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D
ysregulation of the molecular pathways involved in
the self-renewal, differentiation and proliferation of hae-
matopoietic stem cells (HSCs) can cause leukaemia.
Notably, the serine/threonine kinase Akt, which acts downstream
of PI3 kinase (PI3K), is hyper-phosphorylated in up to 80% of acute
myeloid leukaemia (AML) cases1. This is unlikely to be due to
mutations in upstream receptor tyrosine kinases alone. In chronic
myelogenous leukaemia, PI3K/Akt signalling can also be activated
through downregulation of the phosphatase and tensin homologue
(PTEN) by BCR–ABL2. PTEN is a lipid phosphatase that
counteracts PI3K signalling by dephosphorylating phosphatidy-
linositol-3,4,5-trisphosphate (PIP3). PTEN is frequently inactivated
in haematological malignancies3,4, including in AML and T cell
acute lymphoblastic leukemia (T-ALL)5. Notably, PTEN expression
is often reduced in the disease through several other modes of
PTEN regulation, for example, microRNAs, epigenetic
modiﬁcations and ubiquitination6–9, which likely contribute to
the high frequency of Akt phosphorylation in myeloid leukaemia.
In mice, genetic ablation of PTEN in the haematopoietic
system leads to HSC depletion in the bone marrow (BM),
myeloproliferative neoplasia (MPN) and transplantable acute
leukaemia (myeloid or T-cell leukaemia)10–12. In patients, MPNs
such as chronic myelogenous leukaemia or myeloﬁbrosis can
progress to AML13.
Class I PI3Ks are heterodimeric lipid kinases that produce the
lipid second messenger PIP3 on stimulation of cells by many
growth factors. Class I PI3Ks are divided into class IA (p110a,
p110b and p110d) and class IB (p110g) enzymes; of these,
the p110a and p110b isoforms are ubiquitously expressed, while
p110d and p110g are enriched in leukocytes. Work in several
different murine models has documented distinct requirements for
different PI3K isoforms in particular tumour types14,15. For
example, p110a is essential in a model of mutant Kras-induced
lung adenocarcinoma16. Recently, we showed that Ras-mutated
myeloid leukaemia is also dependent on the p110a isoform, and
combined pharmacologic inhibition of p110a and mitogen-
activated protein kinase kinase (MEK) could be an effective
therapeutic strategy for Ras-mutated myeloid malignancies17.
Although p110b plays a less prominent role in receptor tyrosine
kinase (RTK) signalling, it mediates G protein-coupled receptor
(GPCR) and integrin signalling18–20, and has been shown to
interact speciﬁcally with Rho family GTPases Rac1 and CDC42 (ref.
21). Several recent studies demonstrated that p110b is required in
many, but not all, PTEN-deﬁcient solid tumours20,22,23. However, it
is not known which PI3K isoforms are most important for myeloid
neoplastic transformation driven by PTEN loss.
A number of pan-class I PI3K and dual class I/mTOR inhibitors
are now in clinical trials for cancer, including leukaemia. However,
targeting PI3K with these inhibitors could potentially lead to severe
toxicity, which could be prevented by targeting single PI3K
isoforms. To this end, numerous isoform-selective compounds are
currently under development with some already in clinical trials14.
The p110d-selective inhibitor idelalisib (referred to here as
GS1101) has been remarkably effective in treating indolent B-cell
malignancies, and is now approved by the FDA for the treatment
of chronic lymphocytic leukaemia24. In the case of solid tumours,
p110a-selective inhibitors have shown great promise in early-phase
trials for patients with tumours bearing PIK3CA mutations14.
Notably, selective inhibitors of p110b are in clinical trials as
anticancer reagents for advanced solid tumours with PTEN
deﬁciency (NCT01458067). Thus, unravelling the role of each
PI3K isoform, and its contribution to leukaemic transformation
driven by PTEN loss, would inform rational approaches in
targeting the PI3K pathway with a better therapeutic window.
In the present study, we used genetically engineered mouse
models to determine which of the class IA PI3K isoforms are
most important in mediating the effects of Pten loss in HSCs. We
show that, in the setting of Pten loss, p110b is the main PI3K
isoform responsible for MPN development and HSC depletion in
the BM. Furthermore, we show that isoform-selective PI3K
inhibitors recapitulate our genetic ﬁndings. We also found that a
signalling loop featuring p110b and Rac plays an important role
in the absence of Pten. Our results suggest that targeting p110b
and/or Rac may lead to an effective therapeutic strategy for
PTEN-deﬁcient myeloid leukaemia.
Results
p110b ablation prolongs survival of Mx-1-Cre;Ptenﬂ/ﬂ mice. To
explore the roles of the class IA PI3K isoforms in HSCs and
leukaemic transformation in the absence of Pten, we crossed
Mx-1-Creþ ;Ptenﬂ/ﬂ mice10,11 with strains that carry homozygous
ﬂoxed alleles of p110a (ref. 25) or p110b (ref. 20), or with a p110d
germline knockout strain26 to allow for simultaneous deletion of
Pten and PI3K isoforms in HSCs. As Mx1 is an interferon-
responsive promoter expressed in HSCs and all other
haematopoietic cells, the expression of Cre recombinase can be
induced by administration of double-stranded RNA polyI-polyC
(pIpC), which induces an interferon response10,27. Mx-1-Creþ ;
Ptenﬂ/ﬂ (PtenD/D), Mx-1-Creþ ;Ptenﬂ/ﬂ;p110aﬂ/ﬂ (PtenD/D;
p110aD/D), Mx-1-Creþ ;Ptenﬂ/ﬂ;p110bﬂ/ﬂ (PtenD/D;p110bD/D)
and Mx-1-Creþ ;Ptenﬂ/ﬂ;p110dKO/KO (PtenD/D;p110d / ) mice
were treated with pIpC to induce Cre-mediated excision of ﬂoxed
alleles at 4 weeks of age (Supplementary Fig. 1a). This leads to the
deletion of Pten and/or PI3K isoforms in haematopoietic cells,
including HSCs or progenitor cells in the BM, spleen, thymus and
liver11.
Consistent with previous studies10,11, all PtenD/D mice
developed MPN and reached the survival end point 20–40 days
post injection (DPI; Fig. 1a). PtenD/D;p110aD/D and PtenD/D;
p110d / mice also developed MPN with slightly extended
survival (Fig. 1a). Notably, PtenD/D;p110bD/D mice lived the
longest, with median survival signiﬁcantly longer than that of any
other group (Fig. 1a). Further observation revealed that, whereas
control, PtenD/D, PtenD/D;p110aD/D and PtenD/D;p110d /
animals developed MPN, six out of nine PtenD/D;p110bD/D mice
succumbed to T-ALL (Fig. 1b). BM from the three PtenD/D;
p110bD/D mice that did develop MPN was analysed for excision
of the pik3cb allele. Notably, we found that BM of these mice had
incomplete deletion of Pik3cb alleles suggesting that p110b
is critical for the development of MPN in this model
(Supplementary Fig. 1b). Deletion of p110b in HSCs using
Mx1–Cre in animals that are wild-type (WT) for Pten does not
signiﬁcantly affect blood counts (Supplementary Fig. 1c).
Histopathological analysis of moribund animals of PtenD/D,
PtenD/D;p110aD/D and PtenD/D;p110d / mice at 20–40 days
post pIpC showed that they developed massive splenomegaly with
a marked increase in cells expressing myeloperoxidase, a marker
used to detect leukaemic cells of the myeloid lineage, in both the
spleen and liver (Supplementary Fig. 2a), conﬁrming MPN
development in these mice. Notably, thymuses in these moribund
mice appeared normal (Supplementary Fig. 2b). However, most
PtenD/D;p110bD/D animals became moribund at 50–70 days post
pIpC with markedly increased thymus weights (Supplementary
Fig. 2b), inﬁltration of terminal deoxynucleotidyl transferase-
positive T lymphoblasts (CD4þ or CD4 and CD8 double-positive
T-cell blasts) in the thymus and BM and increased white blood
cell counts (Supplementary Fig. 2a,c–e), all of which are
manifestations of T-ALL. These results suggest that the p110b
isoform of PI3K plays a uniquely important role in driving
myeloid neoplastic transformation in mice with Pten-deﬁcient
HSCs, but does not contribute to the development of T-ALL in
this murine model.
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Previous studies have shown that Pten deletion in T-cell
progenitors causes malignant transformation in the thymus and
leads to T-cell lymphoma/T-ALL within 50–150 days28,29. Mice
with Mx1–Cre-mediated deletion of PtenD/D, PtenD/D;p110aD/D or
PtenD/D;p110d / showed inﬁltrating MPN disease and became
moribund within 20–40 days after pIpC, earlier than the disease
latency for T-cell disease development. Since PtenD/D;p110bD/D
mice did not develop MPN, they survived longer and developed
T-cell lymphoma/T-ALL B50–70 days post pIpC injection, a
timeline consistent with previous reports on T-cell lymphoma/
T-ALL formation in models of Pten loss in T-cell progenitors28,29.
This suggests that p110b ablation does not prevent T-ALL
formation driven by Pten loss.
To examine further the PI3K isoform dependence in
T-ALL induced by Pten loss, we investigated the roles of
p110a and p110b in a different T-ALL model driven by
Pten ablation in T-cell progenitors using Lck–Cre30.
Interestingly, deletion of either p110a or p110b had no
effect on T-ALL in this model 3 (Supplementary Fig. 2f).
These results underscore the distinct roles of p110b in
myeloid and lymphoid neoplasia induced by Pten deletion in
haematopoietic cells.
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Figure 1 | Ablation of p110b prolonged survival of animals on Pten loss. (a) Survival of PtenD/D (blue; n¼ 9; median survival¼ 26 days), PtenD/D;p110aD/D
(green; n¼9; median survival¼ 31 days), PtenD/D;p110bD/D (red; n¼9; median survival¼ 55 days), PtenD/D;p110d / (orange; n¼ 7; median
survival¼ 37 days) and control animals (black) represented as DPI. The log-rank test was used to compare survival between groups. (b) Survival time and
the development of MPN and T-ALL in each group of mice as indicated. Survival of PtenD/D (n¼ 9; median survival¼ 26 days), PtenD/D;p110aD/D (n¼ 9;
median survival¼ 31 days), PtenD/D;p110bD/D (n¼ 9; median survival¼ 55 days), PtenD/D;p110d / (n¼ 7; median survival¼ 37 days) and control animals
(black) represented as DPI. Black dots represent MPN disease cases and red dots represent T-ALL cases in each group. The log-rank test was used to
compare survival between groups. (c) Histopathology of the spleen ( 1 and 40) and liver ( 100) taken at 26 DPI. Increased splenomegaly and
disruption of spleen architecture as well as increased myeloid cell inﬁltration after Pten deletion. Scale bar, 5 mm. (d) Total cellularity of the spleen is
represented as mean±s.d. of n¼ 5 except PtenD/D;p110d / (n¼ 10). Two-way ANOVA test was applied to compare the spleen cellularity. (e)
Representative ﬂow cytometry plots of Mac1þGr1þ cells in the spleen. Samples were analysed at 26 DPI. Bar graphs represent the mean±s.d. of n¼9
(PtenD/D;p110d / ), 10 (PtenD/D;p110aD/D), 11 (ctrl) or 13 (PtenD/D and PtenD/D;p110bD/D). Two-way ANOVA test was applied to compare the Mac1-Gr1
cells in the spleen. *Po0.05, **Po0.01, ***Po0.001
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p110b mediates myeloid expansion induced by Pten loss. To
further characterize disease in the PtenD/D;p110D/Dmice, we killed
mice of each genotype at 26 DPI, the time point at which the
PtenD/D mice become moribund. Similar to previous reports, all
animals in the PtenD/D group displayed massive splenomegaly,
increased spleen cellularity and loss of spleen architecture at this
time point (Fig. 1c,d). Both PtenD/D;p110aD/D and PtenD/D;
p110d / mice showed evidence of MPN similar to that of
PtenD/D mice, suggesting that ablation of p110a or p110d failed to
rescue this disease phenotype. Notably, PtenD/D;p110bD/D mice
had signiﬁcantly reduced spleen cellularity and size, compared
with PtenD/D mice (Fig. 1c,d). Consistently, pathological analysis
of the spleen and liver revealed inﬁltration of myeloid cells in
PtenD/D, PtenD/D;p110aD/D and PtenD/D;p110d / animals, but
not in PtenD/D;p110bD/D mice (Fig. 1c). Flow cytometric analysis
conﬁrmed an increased population of myeloid cells (Mac1þ
Gr1þ ) in the BM, spleen and peripheral blood of PtenD/D animals
(Fig. 1e; Supplementary Fig. 3). Again, the numbers of Mac1þ
Gr1þ cells in these organs in PtenD/D;p110bD/D but not in
PtenD/D;p110aD/D and PtenD/D;p110d / animals were con-
sistently reduced compared with those of PtenD/D mice (Fig. 1e;
Supplementary Fig. 3), suggesting that ablation of p110b
suppressed myeloid cell expansion on Pten loss.
To further validate the role of p110b in the myeloid expansion
caused by Pten loss, we performed colony assays in methylcellu-
lose supplemented with myeloid growth factors. Compared with
wild-type controls, both BM and spleen cells from PtenD/D
animals generated an increased number of colonies, which was
signiﬁcantly reduced in PtenD/D;p110bD/D mice (Fig. 2a).
Together, these results demonstrate that p110b is required for
MPN development in the absence of Pten.
To determine whether the contribution of p110b to myeloid
neoplasia in the absence of Pten is a cell-autonomous or indirect
effect, we transplanted whole BM cells from PtenD/D, PtenD/D;
p110bD/D or control mice into recipient mice (Fig. 2b). Four
weeks after transplantation, all groups were treated with pIpC,
and the relative frequency of CD45.2þ donor-derived Mac1þ
Gr1þ cells was monitored over 16 weeks. The proportion of
PtenD/D donor-derived myeloid cells expanded signiﬁcantly 4
weeks after pIpC and remained elevated during the course of the
experiment. In contrast, the PtenD/D;p110bD/D donor-derived
myeloid population remained stable during the entire experiment,
with levels much comparable to that of wild-type control mice
(Fig. 2c). There were no signiﬁcant differences in the percentage
of donor-derived CD3-positive T cells among any of the groups
tested (Supplementary Fig. 4a). The percentage of donor-derived
B220-positive B cells was reduced after Pten deletion, and
deletion of p110b did not alter B-cell chimaerism (Supplementary
Fig. 4b). These data suggest that p110b mediates the expansion of
myeloid cells in a cell-autonomous manner.
p110b perturbs HSC homeostasis on loss of Pten. Earlier studies
showed that HSC-speciﬁc deletion of Pten leads to the exhaustion
of HSCs in the BM, their accumulation in the periphery and
extramedullary haematopoiesis10,11. Hence, we wanted to test
whether p110b ablation could rescue HSCs. In PtenD/D mice, the
numbers of both the LinSca-1þ c-kitþ (LSK) cells, containing
HSCs and the CD150þCD48LinSca-1þ c-kitþ population,
which is enriched for long-term HSCs (LT-HSCs) were
signiﬁcantly reduced at 26 DPI, consistent with previous
ﬁndings11 (Fig. 3a; Supplementary Fig. 5a). Ablation of p110b
was able to partially rescue LSK cells and restore LT-HSCs in
Pten-null BM (Fig. 3a). Loss of Pten did not change the total
number of myeloid progenitors, or the frequencies of the
common myeloid progenitors and granulocyte macrophage
progenitors or megakaryocyte-erythroid progenitors, but led to
a signiﬁcant decrease in the number of common lymphoid
progenitors consistent with original reports11 (Supplementary
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Fig. 5b). This decrease in the number of common lymphoid
progenitors in the Pten-deﬁcient BM was not rescued by the
deletion of p110b (Supplementary Fig. 5b).
To determine whether p110b is responsible for the increased
extramedullary haematopoiesis in the spleen seen after Pten loss,
we measured the frequency and absolute numbers of HSCs and
progenitors in the spleens of PtenD/D and PtenD/D;p110bD/D
animals. Pten deﬁciency led to a signiﬁcant increase in the
number of LSK cells, as well as LT-HSCs, short-term HSCs
(ST-HSCs) and progenitors in the spleens of PtenD/D animals
(Fig. 3b; Supplementary Fig. 5c,d)11,31, which was partially
suppressed in the spleens of PtenD/D;p110bD/D animals (Fig. 3b;
Supplementary Fig. 5c,d). These results suggest that deletion of
p110b normalizes the distribution of phenotypic LSK cells
between the BM and extramedullary tissues in PtenD/D;p110bD/D
animals compared with PtenD/D controls. Thus, our ﬁndings are
consistent with the idea that p110b contributes to the perturbed
HSC homeostasis observed in the absence of Pten leading to
extramedullary haematopoiesis and the development of MPN.
p110b mediates leukaemia initiation in the absence of Pten. It
has been reported that Pten loss in the BM leads to the depletion of
HSCs and the generation of leukaemia-initiating cells10,11. To
determine whether the p110b isoform also uniquely plays critical
roles in these processes in the Pten-loss setting, we performed
competitive multi-lineage repopulation assays to compare the
contribution of marked (CD45.2) PtenD/D, PtenD/D;p110aD/D,
PtenD/D;p110bD/D donor BM cells to that of wild-type competitor
cells (CD45.1) following transplantation into lethally irradiated
mice. Consistent with earlier reports, the contribution of donor-
derived cells to the peripheral blood was progressively decreased
and eventually depleted for PtenD/D donors, but not for control
donors10,11 (Fig. 4a). HSCs derived from PtenD/D;p110aD/D mice
also failed to sustain long-term reconstitution. In striking contrast,
Bone marrow
WT
a
b
WT
NS
NS NS
NS
ST-HSC
ST-HSC
LT-HSC
LT-HSC
WT
WT
WT
WT WT
WT
0.12
0.09
0.009
0.006
0.003
0.000
0.06
0.03
0.03
0.00
0.00
0.0
0.08
0.06
0.06
0.04
0.04
0.02 0.02
0.00 0.00
0.1
0.2
0.3
0.01
0.02
Ce
lls
 (×
10
6 )
Ce
lls
 (×
10
6 )
Ce
lls
 (×
10
6 )
Ce
lls
 (×
10
6 )
Ce
lls
 (×
10
6 )
Ce
lls
 (×
10
6 )
LSK
LSK
*
*
*
***
***
***
**
**
*
*** **
*
* *
Sca-1
Sca-1
105
105
104
104
103
103
0
105
105
104
104
103
103
0
105
104
103
0
105
104
103
0
0
105
104
103
0
105
104
103
0
0
1051041030
1051041030
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
105
104
103
0
1051041030 1051041030
105104103
<PerCP-Cy5–5-A> <PerCP-Cy5–5-A> <PerCP-Cy5–5-A>
1051041030
1051041030
1051041030
1051041030
CD150
Spleen
CD
48
c-
Ki
t
CD
48
c-
Ki
t
LSK
LSK
ST-HSC LT-HSC
1051041030
CD150
ST-HSC LT-HSC
PtenΔ/Δ
PtenΔ/Δ
PtenΔ/Δ
PtenΔ/Δ
PtenΔ/Δ
PtenΔ/Δ PtenΔ/Δ
PtenΔ/Δ
Pten Δ/Δ;
p110β Δ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
PtenΔ/Δ;
p110βΔ/Δ
Figure 3 | p110b deletion restores HSCs to both the bone marrow (BM) and the spleen. (a) Representative ﬂow cytometric plots of ctrl, PtenD/D
and PtenD/D;p110bD/D BM showing LSK cells (Lin–Sca-1þc-kitþ ), ST-HSC (CD150–CD48 LinSca-1þ c-kitþ ) and LT-HSC (CD150þCD48Lin
Sca-1þc-kitþ ) cells (left panels) gated on total living CD45.2þ Lin– cells. Total counts LSK (top) and LT-HSC (bottom right) of lineage-negative cells
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HSCs derived from PtenD/D;p110bD/Dmice were able to reconstitute
recipient animals for more than 20 weeks (Fig. 4a). In addition, the
majority of PtenD/D and PtenD/D;p110aD/D-recipient mice developed
T-ALL as evidenced by the abundance of donor-derived CD45.2þ
CD3þ ;CD4þ or CD3þCD4 T lymphoblasts at the experimental
end point of 20 weeks in these mice (Fig. 4b; Supplementary Fig. 6).
In contrast, recipients of BM from wild-type control mice and from
the majority of PtenD/D;p110bD/D animals remained leukaemia free
with few CD45.2þCD3þ cells at the experimental end point
(Fig. 4b; Supplementary Fig. 6). Furthermore, analysis of the
BM at week 20 showed that the donor chimaerism in the LSK,
ST-HSC and LT-HSC compartments was signiﬁcantly improved
in the PtenD/D and PtenD/D;p110aD/D groups (Fig. 4c).
These data suggest that, in the absence of Pten, p110b is the
major PI3K isoform critical for the loss of HSCs and for leukaemia
initiation.
To determine the cellular mechanism underlying the improved
reconstitution of Pten-null BM cells on loss of p110b, we
examined the cell cycle status, senescence, apoptosis and homing
properties of HSCs. As reported earlier, we also found that loss of
Pten led to increased cycling of HSCs and reduced the number of
quiescent HSCs (Supplementary Fig. 7a)11. Although ablation of
p110b resulted in a tendency towards rescuing these effects,
the results did not reach statistical signiﬁcance (Supplementary
Fig. 7a). Moreover, we did not observe any change in the
proportion of whole BM or LSK cells expressing senescence-
associated b-gal activity or undergoing apoptosis in any of the
groups tested (Supplementary Fig. 7b,c). We then performed
homing assays, in which ﬂuorescently labelled BM cells were
transplanted into irradiated wild-type hosts, and donor-derived
cells were quantiﬁed after 24 h. We found that Pten deﬁciency
signiﬁcantly reduced the homing capacity of transplanted cells to
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the BM, and p110b ablation could partially rescue the homing
potential (Fig. 4d). We also found that p110b ablation does not
affect homing in Pten-wild-type BM cells (Fig. 4d). Thus, we
conclude that p110b is responsible, at least in part, for the
reduced homing activity of Pten-deﬁcient HSCs.
Inhibition of p110b suppresses myeloid leukaemogenesis.
To determine whether our ﬁndings using a genetic method could
be recapitulated by pharmacologic approaches utilizing PI3K iso-
form-selective inhibitors at effective doses as published in earlier
studies, we ﬁrst examined the effects of PI3K isoform inhibition on
myeloid progenitor function. We cultured BM cells and spleno-
cytes from PtenD/D animals in methylcellulose supplemented with
myeloid growth factors in the presence of PI3K inhibitors. As
reported in previous studies10, the pan-PI3K inhibitor GDC0941
and the mTOR inhibitor RAD001 signiﬁcantly suppressed the
increased colony formation arising from Pten deletion in a dose-
dependent manner (Fig. 5a). Consistent with our genetic ﬁndings,
inhibition of p110a with BYL719 (a p110a-selective inhibitor)32
and p110d with GS1101 (ref. 33) had a modest effect on the
expansion of myeloid cells in the context of Pten loss (Fig. 5a).
Since p110g is also expressed in leukocytes, we tested the p110g
inhibitor NVSPI35 (ref. 34). Interestingly, inhibition of p110g with
NVSPI35 showed some effect on BM cells, but not on splenocytes
(Fig. 5a). Notably, inhibition of p110b with KIN193 (a p110b-
selective inhibitor, also known as AZD6482)14,22 signiﬁcantly
reduced formation of both BM- and spleen-derived myeloid
colonies in methylcellulose in a dose-dependent manner (Fig. 5a)
suggesting that pharmacologic inhibition of p110b is highly
effective in suppressing myeloid cell expansion driven by Pten loss.
To further determine the effects of pharmacologic inhibition
of PI3K isoforms in vivo, we treated a group of pIpC-induced
PtenD/D animals with BYL719, KIN193, IC87114 (a p110d-
selective inhibitor in the same class as GS1101, but with better
bioavailability in mice)35, AS605240 (p110g-selective inhibitor
suitable for in vivo studies)36 or a vehicle control 10 days after
induction (Fig. 5b). All the inhibitors were used at the effective
doses in vivo as published in earlier studies36–38. Treatment with
BYL719 (ref. 37), IC87114 (ref. 38) or AS605240 (ref. 36) resulted
in a minimal survival beneﬁt compared with vehicle-treated
animals (Fig. 5c). Notably, mice treated with KIN193 had a
signiﬁcantly longer survival as compared with mice in any other
group (Fig. 5c). Moreover, KIN193-treated animals appeared
healthy and had signiﬁcantly reduced spleen weights and normal-
looking spleen architecture compared with vehicle-treated mice
(Fig. 5d; Supplementary Fig. 8), consistent with our genetic data
that ablation of p110b largely prevented myeloid leukaemia in
Pten-deﬁcient mice.
Next, we examined PI3K/Akt signalling in Pten-null BM cells
in response to isoform-selective inhibition. As expected, vehicle-
treated Pten-null BM cells from PtenD/D animals showed
markedly increased Akt phosphorylation compared with
wild-type BM cells (Fig. 5e). Interestingly, inhibition of either
p110a, p110b or p110d led to a signiﬁcant reduction of p-Akt,
compared with the controls (Fig. 5e). We also examined
Akt activation by measuring basal p-Akt levels in LSK cells by
intracellular phosopho-ﬂow cytometry after Pten deletion and
short-term isoform-selective inhibitor treatment of lineage-
negative cells from PtenD/D BM. We detected signiﬁcantly higher
basal levels of p-Akt in PtenD/D LSK cells compared with
WT LSKs, and again inhibition of p110a, p110b, p110d or
p110g led to a signiﬁcant reduction of p-Akt compared with
the vehicle group (Fig. 5f). Since p110b is not the only
isoform responsible for mediating Akt signalling in Pten-deﬁcient
BM and HSCs, Akt signalling alone is not sufﬁcient to explain the
speciﬁc biological effects of p110b ablation or inhibition observed
in our study.
Pten-deﬁcient HSCs depend on the p110b–Rac axis. Recent
data suggested that p110a, p110d and p110g bind to and are
activated by the Ras subfamily of GTPases, while p110b instead
binds to and is activated by the Rho subfamily GTPases, Rac1 and
CDC42 via its ‘Ras-binding domain’ (RBD)17,21. Previous studies
also reported that an intact RBD was required for signalling and
oncogenic transformation by wild-type p110b, suggesting a
potential role for the interaction of Rho GTPase with p110b in
transformation39,40. Notably, Rac1 and CDC42 can also be
activated downstream of PI3K by PIP3-dependent guanine-
nucleotide exchange factors41,42. It has been previously reported
that Rac plays important roles in the homing and survival of
HSCs43,44. Given the signiﬁcant rescue of HSCs in PtenD/D;
p110bD/D mice, we hypothesized that a unique positive-feedback
signalling loop might exist between p110b and Rac, in which
p110b is activated by Rac and Rac could in turn be activated by
the phosphoinoside products of p110b in the setting of Pten-null
haematopoietic cells.
Notably, we detected higher levels of Rac–GTP in the BM of
PtenD/D mice, which could be suppressed by deletion of p110b
but not p110a (Fig. 6a). To investigate whether the binding of
p110b to Rac is important in mediating p110b activity in Pten-
deleted BM cells, we mutated the two highly conserved key
residues within the p110b RBD to generate a p110b–S205D/
K224A double mutant lacking the binding activity to Rac1 (ref.
21), and performed an add-back experiment with either wild-type
or RBD-mutant p110b in BM cells derived from PtenD/D;p110bD/
D mice (Fig. 6b; Supplementary Fig. 10). Colony-forming assays
revealed that, while adding back a wild-type p110b in PtenD/
D;p110bD/D BM cells restored myeloid colony numbers compar-
able to those of PtenD/D BM cells, the RBD-mutant p110b failed
to rescue colony formation (Fig. 6c). To determine whether
p110b affects Rac–GTP levels in HSCs/progenitor cells (HSPCs),
we performed the Rac–GTP assay either on Lin-negative PtenD/D
BM cells or PtenD/D;p110bD/D cells expressing wild-type p110b
and RBD-mutant p110b. We detected higher levels of Rac–GTP
in the Pten-deﬁcient cells compared with WT control cells, and
these levels were signiﬁcantly reduced in PtenD/D;p110bD/D cells.
Adding back wild-type p110b to PtenD/D;p110bD/D HSC/P cells,
partially rescued Rac–GTP levels but adding back RBD-mutant
p110b failed to rescue Rac activity (Fig. 6d; Supplementary
Fig. 10) Together, these data suggest that the interaction of p110b
with Rac plays an important role in mediating the myeloid
clonogenic activity driven by Pten loss.
To further investigate the functional dependency of
Pten-deleted leukaemic cells on the p110b–Rac axis, we utilized
NSC23766, a potent Rac inhibitor45 in our Pten-null model
(Fig. 7a). We found that treatment of these mice for 10 days led
to a reduced disease burden, as demonstrated by reduced
spleen size and cellularity (Fig. 7a; Supplementary Fig. 9).
Similarly, treatment of PtenD/D mice with NSC23766 resulted
in a signiﬁcant reduction of HSC and myeloid progenitor
numbers in the spleen compared with vehicle controls (Fig. 7b;
Supplementary Fig. 9). Treatment with NSC23766 also led
to a signiﬁcantly prolonged survival of PtenD/D mice (Fig. 7c),
recapitulating the ﬁndings for genetic ablation or
pharmacological inhibition of p110b in Pten-null animals.
Since Rac is required for p110b activation downstream of
GPCRs21, we assessed the functional importance of the
Rac–p110b signalling axis in HSPC function in response to
activation of CXCR4, a GPCR important in the regulation of
HSPCs. We used Transwell migration assays with CXCL12, a
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potent chemo-attractant of stem cells that signals through
CXCR4. Lineage-negative BM cells from PtenD/D mice showed
increased migration towards CXCL12 compared with WT control
cells (Fig. 7d). This migration was abolished by the GPCR
inhibitor pertussis toxin (PTX; Fig. 7d). Interestingly, we observed
signiﬁcantly reduced migration of PtenD/D;p110bD/D cells, and of
PtenD/D cells treated with either KIN193 or NSC23766, compared
with PtenD/D and PtenD/D;p110aD/D cells (Fig. 7d). This suggests
that deletion of p110b, or pharmacologic inhibition of either
p110b or Rac, partially interferes with the migration of PtenD/D
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GDC0941 or RAD001 with the following concentrations based on published data: 1, 0.5, 0.1 mM (BYL719, TGX221 and GDC0941); 5, 1, 0.5mM (GS1101);
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cells towards a CXCL12 gradient, likely through perturbed GPCR
signalling.
Because murine models of haematopoietic-speciﬁc Rac1 and
Rac2 deﬁciency have revealed differential roles of Rac proteins in
terms of HSPC function, we wanted to understand which Rac
isoform is more important in the absence of Pten. To this end, we
used siRNA to knockdown either Rac1 or Rac2, or both, and
performed colony assays on PtenD/D and PtenD/D;p110bD/D BM
cells (Fig. 7e,f; Supplementary Fig. 10). We also tested the Rac
inhibitor NSC23766, which targets both Rac1 and Rac2 (ref. 46).
Knockdown of either Rac1 or Rac2, or their combined
knockdown or pharmacological inhibition signiﬁcantly reduced
colony formation by PtenD/D cells to levels obtained with PtenD/D;
p110bD/D BM cells (Fig. 7f). However, knockdown of Rac1 or
Rac2, the combination, or NSC23766 treatment did not further
suppress colony formation beyond the effects of p110b deletion
(Fig. 7f), suggesting that there is no additive or synergistic effect
of Rac inhibition with p110b deﬁciency in PtenD/D cells. Together,
these results suggest that p110b–Rac1/2 work in concert to
mediate the effects of Pten loss in promoting myeloid neoplasia.
Discussion
We and others have reported that Pten-deﬁcient solid tumours
frequently rely on p110b (refs 20,23,47). In this study, we report
for the ﬁrst time an essential role for p110b in promoting
haematologic neoplasia driven by Pten deletion in HSCs despite
the expression of four different PI3K isoforms in haematopoietic
cells. We have also found that p110b contributes to HSC depletion
in the BM after Pten deletion. Interestingly, we found that Mx1–
Cre-mediated deletion of p110b in HSPCs of animals that are WT
for Pten does not signiﬁcantly affect blood counts. In fact, these
animals appear healthy for many months after excision, suggesting
that targeting p110b may lead to an effective therapy for myeloid
leukaemia with little toxicity to normal HSCs.
Despite the marked impact of genetic deletion or pharmaco-
logic inhibition of p110b on MPN, and the signiﬁcantly delayed
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Figure 7 | Pten-deﬁcient haematopoietic cells depend on the p110b–Rac1 signalling axis. (a) NSC23766 was given at 2.5mg g 1 daily intraperitoneally
(IP). Spleen size and cellularity of vehicle-treated (n¼ 3) and NSC23766-treated PtenD/D animals (n¼ 3) at 17 DPI. *Po0.05; **Po0.001; ***Po0.0001.
Two-way ANOVA test was applied to compare spleen size. (b) Quantiﬁcation of the numbers of LSK (Lin–Sca-1þ c-kitþ ), ST-HSC (CD150–CD48Lin
Sca-1þ c-kitþ ) or LT-HSC (CD150þCD48 LinSca-1þ c-kitþ ) cells in the spleens of control, PtenD/D animals treated with vehicle, or PtenD/D animals
treated with NSC23766 at 17 DPI, determined by ﬂow cytometry. The numbers represent total cell counts per spleen (n¼ 3; ctrl, PtenD/D vehicle and
NSC23766 treated). (c) Survival of PtenD/D animals treated with vehicle (blue; n¼ 7; median survival¼ 22 days) or NSC23766 (red; n¼ 7; median
survival¼42 days). **Po0.005. The log-rank test was applied to compare survival. (d) Lineage-negative BM cells were isolated from control, PtenD/D or
PtenD/D:P110bD/D PtenD/D:P110aD/D on 7 DPI, and lineage-negative cells were pretreated for 3 h with KIN193, NSC23766 (50mM) or pertussis toxin (PTX;
100ngml 1). Migration towards the lower chamber (supplemented with CXCL12, 50nM) was measured as the fraction of migrated cells relative to untreated
Pten-null bone marrow-derived cells. Numbers of replicates are n¼4 (basal, PtenD/D no Cxcl12; PtenD/Dþ PTX), 10 (PtenD/D), 6 (PtenD/D:P110bD/D) and 6
(PtenD/DþKIN193). Statistical comparisons were all performed relative to the PtenD/D group. (e) PtenD/D and PtenD/D;p110bD/D BM cells were transfected
with two different siRNAs targeting scrambled, mouse Rac1, mouse Rac2 alone, or both Rac1 and Rac2 and subjected to immunoblotting 48h later. (f) PtenD/D
and PtenD/D;p110bD/D BM cells from knockdown were transfected with two different siRNAs targeting scrambled, mouse Rac1, mouse Rac2 alone, or both Rac1
and Rac2, or treated with NSC23766 (50mM) and then colony assays were performed in methylcellulose with myeloid growth factors. Colonies were counted
after 7 days (n¼ 3) for each group. Two-way ANOVA test was applied to calculate colony formation. (g) A working model of signalling cascades downstream
of P110b and the signalling loop of P110b and Rac1.
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onset of leukaemia, a fraction of PtenD/D;p110bD/D animals
succumbed to T-ALL at a later time. Berenjeno et al.48 showed
that in Ptenþ /– animals, inactivation of p110b led to reduced
PIP3 generation in lymphoma tissues, but had little impact
on lymphoma formation. It is possible that these tumours
become p110b independent through the acquisition of secondary
alterations. In fact, Yilmaz et al.10 have documented the presence
of cytogenetic alterations in leukaemic blasts from PtenD/D
animals. Alternatively, isoform dependency may shift with cell
differentiation. For example, the isoform dependency in the
skin hamartoma driven by Pten loss changed from a p110b
dependency in the basal layer of the epidermis to a p110a
dependency in the suprabasal cells as the basal cells underwent
stepwise differentiation to become suprabasal cells37. In this
study, we also provide evidence that neither p110a nor p110b has
any effect on T-ALL driven by T lymphocyte-speciﬁc deletion of
Pten using Lck–Cre. In this system, it has been shown that p110d
and p110g contribute to T-ALL induced by Pten loss in T cells28.
These studies provide additional data that accentuate the distinct
roles of p110b in the HSCs and in myeloid and lymphoid tumour
initiation in the absence of Pten.
Interestingly, we found that inhibition of p110b, p110a or
p110d could similarly reduce p-Akt in Pten-deﬁcient BM and
HSCs, suggesting an Akt-independent pathway speciﬁc to p110b
is important in Pten-deﬁcient HSCs in promoting myeloid
neoplasia. We report a new mechanistic insight that may explain
the unique role of p110b in this setting. Since p110b binds to Rac
rather than to Ras via its RBD, unlike the other class I PI3K
isoforms21, we investigated the role of the p110b–Rac axis in the
setting of myeloid neoplasia induced by Pten loss in HSCs.
Notably, Rac signalling is not only important for the activation of
p110b but it itself is also activated by PIP3 via PIP3-activated
guanine-nucleotide exchange factors, forming a potential
signalling loop (Fig. 7g)14,49. We found strong evidence that
this loop is indeed active in our Pten-deﬁcient model. We show
that Rac was activated in Pten-null BM cells, and this activation
was suppressed in Pten/p110b double KOs, but not in
Pten/p110a double KOs. This hypothesis was further supported
by our ﬁnding that only wild-type p110b, but not the RBD
mutant of p110b, rescued colony formation in Pten/p110b-
deﬁcient BM cells. Notably, the effect of the RBD-mutant p110b
on inhibiting colony formation in Pten-null BM cells is
comparable to that of p110b deletion. An intact RBD was
reported to be required for membrane localization of p110b
for both signalling and oncogenic transformation by wild-type
p110b in cultured cells40. Our data suggest that the interaction of
p110b–Rac may play an important role in mediating p110b
activity downstream of GPCRs and tyrosine kinases in the context
of Pten deﬁciency. Moreover, pharmacologic inhibition of p110b
or Rac in Pten-deﬁcient mice resulted in a strikingly similar
functional rescue in vivo, with a reduction in extramedullary
haematopoiesis in the spleen and improved survival.
Of the three isoforms of Rac family GTPases, Rac2 is expressed
speciﬁcally in haematopoietic cells, while Rac1 and Rac3 are
ubiquitously expressed44,50. The Rac inhibitor NSC23766 targets
all three Rac members: Rac1, 2 and 3 (ref. 46). Both Rac1 and
CDC42 have been shown to bind p110b in a recent study21.
Binding to Rac2/3 was not tested, but might also be expected,
based on the homology of their effector domains with that of
Rac1. Previous studies have suggested that Rac1 and Rac2 play
both distinct and overlapping roles in HSCs and progenitor cells,
while the role of Rac3 in haematopoiesis has not been
deﬁned44,51. It also has been shown that targeting both Rac1
and Rac2 was effective in a mouse model of BCR–ABL-induced
MPN, as well as in a mouse model of MLL–AF9 AML46,52.
Interestingly, our data show that the effect of knockdown of Rac2
is comparable to that of combined knockdown of both Rac1 and
Rac2, or a pan-Rac inhibitor NSC23766. Since Rac2 is primarily
expressed in haematopoietic cells, our data suggest that Rac2
could potentially be a better pharmacologic target with reduced
toxicity.
Yilmaz et al. have shown that the mTOR inhibitor rapamycin
can rescue HSC depletion and can suppress the development of
leukaemia in vivo. More recently, the Armstrong and Morrison
groups reported that mTORC1 and mTORC2 play critical
roles in haematopoiesis and Pten-loss-driven leukaemogenesis,
respectively53,54. By ablation or inhibition of p110b, we obtained
similar results suggesting that the activation of mTOR in HSCs by
Pten loss may be mediated largely by p110b. A recent study
demonstrated that Rac1 regulates the activity of both mTORC1
and mTORC2 (ref. 55), providing a potential Akt-independent
link between p110b–Rac and mTOR. Together, these data suggest
that p110b–Rac acts upstream of Akt and mTOR. We feel that
our data are most consistent with the working model shown in
Fig. 7g, in which p110b works in a signalling loop with Rac to
generate the key signals arising from Pten loss. Notably, these
signals include both Akt-dependent and Akt-independent
pathways leading to cell proliferation and migration.
In summary, our results provide the ﬁrst evidence that
PI3K–p110b plays an essential role in controlling HSC function
in the setting of Pten loss56. We have also uncovered a speciﬁc
role for p110b in myeloid leukaemia induced by Pten deﬁciency.
In contrast, we found that p110b is dispensable for T-ALL
induced by Pten loss. Most importantly, our data show that a
p110b–Rac signalling loop is important for the induction of
myeloid neoplasia in the absence of Pten. Thus, second-
generation p110b- or Rac-selective inhibitors may interrupt this
loop, thereby providing a promising new therapeutic strategy for
Pten-deﬁcient myeloid leukaemias while preserving normal
haematopoiesis.
Methods
Animal experiments. Mice were housed in a pathogen-free animal facility at
Dana-Farber Cancer Institute (DFCI). All animal experiments conformed to the
relevant regulatory standards, guidelines and regulations, and were approved by
the DFCI-Institutional Animal Care and Use Committee (IACUC). Dead and
moribund animals were included in survival curves. Ptenﬂ/ﬂ mice (obtained from
Hong Wu’s Laboratory) were crossed with Ptenﬂ/þ animals carrying an Mx-1-Cre
transgene (obtained from Dr Gary Gilliland’s laboratory) to obtain Mx-1-Creþ ;
Ptenﬂ/ﬂ mice (PtenD/D). p110a and p110b mutants were obtained by crossing
Mx-1-Creþ ;Ptenﬂ/þ mice with p110aﬂ/ﬂ, p110bﬂ/ﬂ animals to obtain Mx-1-Creþ ;
Ptenﬂ/ﬂ;p110aﬂ/ﬂ (PtenD/D;p110aD/D) and Mx-1-Creþ ;Ptenﬂ/ﬂ;p110bﬂ/ﬂ animals
(PtenD/D;p110bD/D). P110d germline knockout animals (James Ihle’s laboratory)
were backcrossed to the C57BL/6 background for more than nine generations and
then crossed with Mx-1-Creþ ;Ptenﬂ/þ to obtain Mx-1-Creþ ;Ptenﬂ/ﬂ;p110d /
animals (PtenD/D;p110d / ). Thirty day-old male and female animals were
induced by intraperitoneal injection with pIpC (25mg g 1; GE Healthsciences)
every other day for 5 days. WT;Mx-1-Creþ mice were used as controls for
all experiments. Peripheral blood was obtained by retro-orbital venous blood
sampling. Peripheral blood counts were analysed on a Hemavet 950FS blood
analyzer (Drew Scientiﬁc).
Flow cytometry. All data acquisition was performed on a LSRII (BD) ﬂow
cytometer, and results were analysed using FlowJo v.8.8.7 (Tree Star). Antibodies
used for ﬂow cytometry were directly coupled and directed against B220 (APC,
BD Pharmingen), cKit (PE-Cy7, BioLegend), CD3 (PE-Cy7, BD Bioscience),
CD4 (APC-H7, BD Pharmingen), CD8 (ECD, Beckman Coulter), CD11b (PE, BD
Bioscience), CD16/32 (PE, eBioscience), CD34 (FITC, BD Pharmingen), CD45.1
(FITC, BD Pharmingen), CD45.2 (PerCP-Cy5.5, BD Pharmingen), CD48
(APC-Cy7, BD Pharmingen), CD127 (ECD, BD Pharmingen), CD150
(PerCP-Cy5.5, BioLegend), Gr1 (APC-Alexa 700, BD Bioscience), lineage cocktail
(APC, BD Pharmingen), Sca1 (Brilliant Violet 421, BioLegend), Ki67 (Alexa 488,
BD Pharmingen). Dead cells were excluded using either DAPI or Vivid-Aqua
(Invitrogen) staining.
Chemotaxis assays. Fresh BM cells were isolated from mutant mice and from
control animals, and lineage-positive cells were depleted using magnetic separation
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(lineage depletion kit, Miltenyi Biotec) and were resuspended in PBS containing
0.5% BSA. Lineage-negative cells (0.5–1million) were pretreated for 3 h at 37 C
with the p110b-speciﬁc inhibitor KIN193 (1mM), NSC23766 (50 mM) PTX from
Bordetella pertussis (100 ngml 1) or dimethylsulphoxide (DMSO; 1:1,000),
or directly loaded (105 cells in 100 ml) in the top chamber of a 6.5-mm diameter
8-mm pore polycarbonate Transwell insert (Corning Costar); inserts with cells were
then placed in wells containing CXCL12 (50mM, PeproTech), and incubated for
3 h at 37 C. Cells migrating from the top to the bottom chamber were collected
and quantiﬁed using a Countess cell counting machine (Invitrogen).
Compounds. TGX221 was obtained from Chemdea; NSC23766 and IC87114 from
Selleck Chemicals; GDC0941 from MedChemexpress; KIN193 from Haoyuan
Chemexpress; NVP-BYL719, NVSPI35, AS605240 and IC87114 were synthesized
by Chemitek (Indianapolis, USA). Mice were dosed once by intraperitoneal
injection of KIN193 (20mg kg 1) formulated in 7.5% NMP (Sigma-Aldrich), 40%
polyethylene glycol 400 (Sigma-Aldrich) and 52.5% dH2O; once by intraperitoneal
injection of NSC23766 (2.5mg kg 1), or gavaged once daily with NVP-BYL719
(45mg kg 1) in 0.5% methylcellulose; AS605240 (50mg kg 1) in 0.5%
carboxymethylcellulose/0.25% Tween-20; or IC87114 (45mg kg 1) dissolved
in 75% polyethylene glycol.
Colony-forming assays. BM and spleen cells were collected, subjected to red-cell
lysis and resuspended in Iscove’s modiﬁed Dulbecco’s medium/10% fetal bovine
serum/5% penicillin–streptomycin. Cells were plated in the presence of inhibitors
in duplicate in M3434 methylcellulose media (Stemcell Technologies) at 1 104
cells per dish for BM and 5 104 cells per dish for spleen cells. Colonies were
scored after 7 days.
Rac activation assay. BM cells from corresponding mice at 7 DPI of pIpC
were collected and immediately subjected to Rac1 activation assay with the Rac1
activation assay kit (Millipore) according to the manufacturer’s instructions.
Western blotting. Whole-cell protein lysates were prepared from single-cell
suspensions of BM and splenocytes from corresponding mice, and from age-
matched WT C57 Bl/6 mice. Western blotting was performed with the slight
changes as follows: 0.45-mM nitrocellulose membranes (Millipore) were used to
transfer the proteins, this followed by blocking 1 h at room temperature in 1TBS,
5% nonfat milk. Primary antibodies used were as follows: p110a (1:1,000, catalogue
no. 4249; Cell Signaling), p110b (1:1,000, catalogue no. sc-602; Santa Cruz), p110d
(1:1,000, catalogue no. sc-55589; Santa Cruz), Akt (1:1,000, catalogue no. 9272; Cell
Signaling), phospho-Akt (Ser473; 1:500, catalogue no. 4050; Cell Signaling), S6
(1:1,000, catalogue no. 2217; Cell Signaling), phospho-S6 (catalogue no. 2211; Cell
Signaling), Rac1 (1:500, catalogue no. 05-389; Millipore), Rac2 (1:500, catalogue no.
sc-96; Santa Cruz), a-HA (1:2,000 catalogue no. H6908; Sigma-Aldrich), a-tubulin
(1:5,000 catalogue no. T9026; Sigma-Aldrich) and vinculin (1:5,000 catalogue no.
sc-73614, Santa Cruz). The directly ﬂuorophore-conjugated secondary antibodies:
anti-mouse 680 and anti-rabbit 800 (LICOR) were used at dilutions of 1:5,000.
LICOR Odyssey instrument was used to develop the membranes. Signal intensity
with background correction was quantiﬁed using LICOR Image Studio software.
Whole Western Blot pictures are shown in Supplementary Fig. 10.
SiRNA knockdown. Two separate SiRNAs, targeting mouse Rac1 (J-041170-05-
0002 and J-041170-06-0002) and Rac2 (J-041171-09-0002 and J-041171-10-0002)
were ordered from Dharmacon (Dharmacon, GE Healthcare) transfected in
Invitrogen X15 media to freshly isolated whole bone marrow (WBM) cells using
RNAiMAX (Invitrogen) in 10-cm plates according to the manufacturer’s instruc-
tions. Forty-eight hours later after transfection, cells were subjected to immuno-
blotting using Rac1 or Rac2 antibodies or colony-forming experiments.
Histology. Recipient mice were killed at the indicated time points, or when they
began to show signs of disease. Organs were ﬁxed in formalin, and histology slides
were prepared and stained at the Brigham and Women’s Rodent Histology Core
Facility. Digital images were acquired on a Nikon Eclipse E400 microscope
equipped with a digital camera and analysed using Spot Advanced software.
Immunohistochemistry. For histological analyses, formalin-ﬁxed tissue sections
were embedded in parafﬁn, sectioned and stained with haematoxylin and eosin by
the Dana-Farber/Harvard Cancer Center Rodent Histopathology Core.
P-Akt ﬂow cytometry analysis of LSK cells. Phospho-ﬂow cytometry was
performed as previously described56, with the following modiﬁcations: lineage-
negative BM cells from mutant animals were isolated using lineage depletion kit
(Miltenyi Biotec) and serum starved for 1 h, and treated for 2 h with 1 mM of
BYL719, KIN193, GS1101 and NVSPI3. Cells were then ﬁxed with 4%
paraformaldehyde, and permeabilized with cold 100% acetone. Cells were than
stained simultaneously with c-kit, Sca-1 and anti-mouse P-Akt (Alexa 647; 1:100
dilution, cat. no. 2337, Cell Signaling). All data acquisition was performed on a
LSRII (BD) ﬂow cytometer, and results were analysed and basal level of P-Akt was
calculated as normalized to WT cells by calculating median ﬂuorescent intensity
using FlowJo v.8.8.7 (Tree Star).
Long-term competitive repopulation assays. Recipient mice (4-6 weeks old
female mice; B6.SJL strain) received two doses of 540 rads each, delivered 3 h apart.
Nucleated BM cells from control and PtenD/D mice (C57 Bl/6) or from compound
mutant mice (PtenD/D; p110aD/D, PtenD/D;p110bD/D and PtenD/D;p110d / ) were
mixed with wild-type competitor BM-nucleated cells (B6.SJL), and were injected
into the retro-orbital venous sinus of irradiated recipients. Peripheral blood was
obtained retro-orbitally every 4 weeks, subjected to red-cell lysis and analysed by
ﬂow cytometry to assess donor cell engraftment for up to 20 weeks after
transplantation. Pilot experiments showed that Pten-mutant animals had a greatly
reduced repopulation capacity; therefore, an excess of mutant cells over control
cells was used. Each recipient mouse received 1 106 Pten mutant, ctrl or com-
pound mutant BM-nucleated cells plus 2 105 competitor cells. Tissues from
recipient mice were collected and stained for pathological examination.
Plasmid constructs. Mutations were generated in the pBabe–HA wild-type P110b
by site-directed mutagenesis to obtain p110b–S205D/K224A double mutant to
obtain Ras-binding mutant P110b. This plasmid was used to transduce PtenD/D;
p110bD/D BM cells and for colony-forming experiments.
Statistical methods. Two-tailed T-tests (two groups) and analysis of variance
(ANOVA) tests (multiple groups) and log-rank statistics (Mantel-Cox test; survival
studies) were used, and calculated with the use of Prism 6.0 (GraphPad). Data are
represented as mean±s.d. unless otherwise noted. *Po0.05; **Po0.01;
***Po0.001.
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